These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15193025)

  • 1. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
    Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
    Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
    Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
    Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.
    Lopez-Gines C; Gil-Benso R; Ferrer-Luna R; Benito R; Serna E; Gonzalez-Darder J; Quilis V; Monleon D; Celda B; Cerdá-Nicolas M
    Mod Pathol; 2010 Jun; 23(6):856-65. PubMed ID: 20305620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
    Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
    Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2-7 gene deletion in human glioblastomas.
    Worm K; Dabbagh P; Schwechheimer K
    Hum Pathol; 1999 Feb; 30(2):222-7. PubMed ID: 10029453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
    Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
    Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
    Liu L; Bäcklund LM; Nilsson BR; Grandér D; Ichimura K; Goike HM; Collins VP
    J Mol Med (Berl); 2005 Nov; 83(11):917-26. PubMed ID: 16133418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
    von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
    Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
    Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
    Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas.
    Furuta T; Negoto T; Miyoshi H; Moritsubo M; Nakamura H; Morioka M; Akiba J; Ohshima K; Sugita Y
    J Neurooncol; 2023 Sep; 164(3):633-641. PubMed ID: 37710025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
    Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
    J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.